Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360
android app
/
iOS App/ web portal.
{
"products": [
{
"_id": "695b65af2800555f6696a6cf",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Cinacalcet 60 mg Tablet",
"description": "CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets\nProduct Overview\nCINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body.\nThe 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet.\nUnderstanding How CINASELECT 60 Works\nCINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream.\nWhen you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH).\nBy lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders.\nPrimary Therapeutic Uses\nSecondary Hyperparathyroidism in Chronic Kidney Disease\nThe primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk.\nCINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues.\nHypercalcemia in Parathyroid Carcinoma\nCINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms.\nPrimary Hyperparathyroidism\nFor patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications.\nKey Benefits of CINASELECT 60\nEffective PTH Control\nClinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification.\nImproved Calcium-Phosphorus Balance\nBy reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life.\nReduced Cardiovascular Risk\nElevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients.\nBone Health Preservation\nUncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density.\nAlternative to Surgery\nFor patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky.\nQuality of Life Improvement\nBy controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity.\nConvenient Oral Administration\nCINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients.\nPotential Side Effects and Adverse Reactions\nCommon Side Effects\nPatients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication.\nDiarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue).\nSerious Side Effects Requiring Medical Attention\nHypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities.\nGastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk.\nAdynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels.\nCardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease.\nAllergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported.\nPrecautions and Contraindications\nCINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH.\nPregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment.\nDosage and Administration Guidelines\nCINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided.\nThe typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved.\nDose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response.\nMonitoring Requirements\nPatients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy.\nAdditionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation.\nStorage and Handling\nCINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package.\nConclusion\nCINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications.\nThe benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management.\nHowever, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.",
"price": 740.0,
"discountamount": 222.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2266,
"imageuri": "https://productimages.withfloats.com/actual/695b65ebf30763183f64d4f7.png",
"tileimageuri": "https://productimages.withfloats.com/tile/695b65ebf30763183f64d4f7.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-01-05T07:18:07.264Z",
"updatedon": "2026-05-01T06:30:26.075Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/cinacalcet-60-mg-tablet/2266",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "CINASELECT 60",
"category": "NEPHROLOGYRANGE",
"tags": [
"cinacalcet 60 mg",
"cinacalcet mechanism of action.",
"cinacalcet uses",
"tab cinacalcet.",
"cinacalcet dose.",
"cinacalcet structure.",
"cinacalcet tab.",
"calcium and phosphorus levels in the bloodstream.",
"parathyroid hormone secretion.",
"calcium metabolism disorders.",
"chronic kidney disease and parathyroid conditions.",
"cinacalcet 60 mg",
"cinacalcet 60",
"Cinacalcet Tablets 60 mg price in India",
"Buy Cinacalcet Tablets 60 mg online",
"Cinacalcet 60 mg wholesale price",
"Buy Cinacalcet Tablets 60 mg",
"Get Cinacalcet Tablets 60 mg at best price"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "694cf85408591c1173b54c2f",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Pregabalin Epalrestat and Methylcobalamin Tablets",
"description": "EPSTATE ED represents an advanced pharmaceutical formulation that combines three powerful therapeutic agents: Pregabalin, Epalrestat, and Methylcobalamin. This innovative triple-combination medication is specifically designed to address the complex pathophysiology of diabetic neuropathy and neuropathic pain conditions. By integrating multiple mechanisms of action, EPSTATE ED offers a comprehensive approach to managing nerve-related complications that significantly impact the quality of life for millions of individuals worldwide.\nThe formulation addresses not only the symptomatic relief of neuropathic pain but also targets the underlying metabolic derangements that contribute to nerve damage progression. This multi-pronged therapeutic strategy makes EPSTATE ED particularly valuable for patients who require more than symptomatic management alone.\nUnderstanding the Active Components\nPregabalin: The Neuropathic Pain Modulator\nPregabalin serves as the cornerstone analgesic component in EPSTATE ED. This anticonvulsant medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Through this mechanism, Pregabalin reduces the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in neurotransmitter release effectively dampens the abnormal neural signaling that characterizes neuropathic pain conditions.\nThe molecule demonstrates excellent bioavailability and rapid absorption, allowing patients to experience relief within a relatively short timeframe. Its efficacy in managing various neuropathic pain syndromes has been extensively documented in clinical trials, establishing it as a first-line agent for diabetic peripheral neuropathy, postherpetic neuralgia, and other chronic neuropathic pain conditions.\nEpalrestat: The Aldose Reductase Inhibitor\nEpalrestat represents a unique addition to the formulation, functioning as a selective aldose reductase inhibitor. In diabetic conditions, excess glucose is converted to sorbitol through the polyol pathway, with aldose reductase serving as the rate-limiting enzyme. The accumulation of sorbitol within nerve cells leads to osmotic stress, depletion of myoinositol, and subsequent nerve dysfunction.\nBy inhibiting aldose reductase, Epalrestat prevents this harmful sorbitol accumulation, thereby addressing one of the fundamental metabolic abnormalities responsible for diabetic neuropathy. This disease-modifying approach distinguishes EPSTATE ED from purely symptomatic treatments. Epalrestat has been particularly well-studied in Asian populations and has demonstrated the ability to improve nerve conduction velocities and reduce subjective neuropathic symptoms over time.\nMethylcobalamin: The Neurotropic Vitamin\nMethylcobalamin, the bioactive form of Vitamin B12, completes the therapeutic triad in EPSTATE ED. Unlike cyanocobalamin, which requires conversion in the body, methylcobalamin is immediately available for utilization in crucial biochemical processes. It plays an indispensable role in myelin synthesis, the protective sheath surrounding nerve fibers that enables proper signal transmission.\nThis coenzyme participates in methionine synthesis and is essential for maintaining the structural and functional integrity of neurons. Methylcobalamin also facilitates nerve regeneration and has demonstrated neuroprotective properties in various experimental models. For patients with diabetic neuropathy, who often exhibit Vitamin B12 deficiency (sometimes exacerbated by metformin therapy), supplementation with methylcobalamin addresses both nutritional deficits and supports nerve health at a fundamental level.\nClinical Applications and Uses\nEPSTATE ED is primarily indicated for the comprehensive management of diabetic peripheral neuropathy, a condition affecting approximately 50% of individuals with long-standing diabetes. The symptoms of this condition range from tingling sensations and burning pain to numbness and loss of protective sensation, which can lead to serious complications including foot ulcers and amputations.\nBeyond diabetic neuropathy, EPSTATE ED may be prescribed for various neuropathic pain syndromes where the combination of pain relief, metabolic correction, and nerve support proves beneficial. Patients experiencing chronic nerve pain resulting from metabolic disturbances, nutritional deficiencies, or structural nerve damage may find this combination particularly effective.\nThe medication is typically recommended for adults who have not achieved adequate symptom control with single-agent therapy or who would benefit from the synergistic effects of the three components. Healthcare providers may prescribe EPSTATE ED when a patient requires both immediate symptom relief and long-term disease modification.\nKey Benefits and Therapeutic Advantages\nComprehensive Multi-Mechanism Action\nThe primary advantage of EPSTATE ED lies in its multi-faceted approach to neuropathic conditions. Rather than addressing only pain symptoms, the formulation simultaneously tackles pain perception, underlying metabolic abnormalities, and nutritional support for nerve health. This comprehensive strategy may lead to superior outcomes compared to monotherapy approaches.\nEnhanced Pain Relief\nClinical evidence supporting Pregabalin's efficacy in neuropathic pain is substantial. Patients often report significant reductions in pain intensity, improved sleep quality due to decreased nocturnal pain, and enhanced ability to perform daily activities. The pain-relieving effects typically manifest within the first week of therapy and continue to improve with ongoing treatment.\nDisease Modification Potential\nUnlike purely symptomatic treatments, the inclusion of Epalrestat provides genuine disease-modifying potential. By targeting the polyol pathway, EPSTATE ED may slow the progression of nerve damage in diabetic patients. Long-term use may preserve nerve function and prevent the worsening of neuropathic symptoms, offering hope beyond mere symptom management.\nImproved Nerve Conduction and Function\nThe combination of metabolic correction through Epalrestat and neurotropic support via Methylcobalamin creates an environment conducive to nerve regeneration and functional improvement. Studies have demonstrated improvements in nerve conduction velocity parameters with similar combination therapies, suggesting potential restoration of nerve function rather than simple symptom masking.\nConvenience of Combination Therapy\nFor patients who would otherwise require multiple separate medications, EPSTATE ED offers the convenience of a single tablet containing all three therapeutic agents. This simplification of medication regimens improves compliance, reduces pill burden, and may enhance overall treatment outcomes.\nQuality of Life Enhancement\nThe cumulative effect of pain reduction, improved nerve function, and better metabolic control translates into meaningful quality of life improvements. Patients report better mobility, reduced interference of pain with daily activities, improved mood, and enhanced social functioning.\nPotential Side Effects and Safety Considerations\nCommon Side Effects\nAs with any pharmaceutical agent, EPSTATE ED may produce certain adverse effects. The most commonly reported side effects are primarily attributable to the Pregabalin component and include dizziness, somnolence, peripheral edema, dry mouth, blurred vision, weight gain, and difficulty with concentration or attention. These effects are generally mild to moderate and often diminish with continued therapy as the body adapts to the medication.\nGastrointestinal symptoms such as constipation or nausea may occur, though they are typically manageable with dietary modifications or symptomatic treatment. Some patients experience increased appetite leading to weight gain, which requires monitoring, particularly in diabetic individuals where weight management is crucial.\nSerious but Rare Adverse Events\nThough uncommon, certain serious adverse effects warrant immediate medical attention. These include allergic reactions manifesting as rash, itching, swelling, severe dizziness, or breathing difficulties. Pregabalin has been associated with rare cases of angioedema, which requires prompt discontinuation and medical intervention.\nMental health changes, including mood alterations, anxiety, depression, agitation, or suicidal thoughts, have been reported with Pregabalin use, particularly in individuals with pre-existing psychiatric conditions. Patients and caregivers should remain vigilant for behavioral changes and report them immediately to healthcare providers.\nDrug Interactions and Precautions\nEPSTATE ED may interact with other central nervous system depressants, including alcohol, opioids, benzodiazepines, and antihistamines, potentially intensifying sedation and cognitive impairment. Patients should inform their healthcare provider of all medications, supplements, and substances they consume.\nIndividuals with kidney impairment require dose adjustments since Pregabalin is primarily eliminated through renal excretion. Regular monitoring of renal function may be necessary during long-term therapy.\nSpecial Population Considerations\nPregnant or breastfeeding women should use EPSTATE ED only when clearly necessary and under strict medical supervision, as the safety profile in these populations has not been fully established. Elderly patients may be more susceptible to side effects, particularly dizziness and confusion, necessitating careful dose titration and monitoring.\nPatients should be advised against abrupt discontinuation of EPSTATE ED, as sudden cessation of Pregabalin may precipitate withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating. Gradual dose reduction under medical supervision is recommended when discontinuing therapy.\nDosage and Administration Guidelines\nThe appropriate dosage of EPSTATE ED is highly individualized and should be determined by a qualified healthcare professional based on the patient's specific condition, response to therapy, and tolerance. Typically, treatment begins with a lower dose that is gradually increased to achieve optimal therapeutic benefit while minimizing adverse effects.\nPatients should take EPSTATE ED exactly as prescribed, with or without food, at consistent times each day to maintain stable blood levels. Missing doses should be addressed by taking the forgotten dose as soon as remembered, unless it's nearly time for the next scheduled dose. Double dosing to compensate for missed doses is not recommended.\nRegular follow-up appointments allow healthcare providers to assess treatment efficacy, monitor for adverse effects, and make necessary dose adjustments. Patients should maintain open communication with their medical team regarding symptom improvement, side effects, and any concerns that arise during therapy.\nPatient Counseling and Lifestyle Recommendations\nMaximizing the benefits of EPSTATE ED extends beyond simply taking the medication. Patients should be counseled on complementary lifestyle measures that support neuropathy management. Maintaining optimal glycemic control remains paramount for diabetic patients, as blood sugar management directly impacts neuropathy progression regardless of medication.\nRegular physical activity, within individual capabilities, promotes circulation, supports nerve health, and may enhance the therapeutic effects of EPSTATE ED. Daily foot examinations become critical for diabetic patients to identify potential injuries early, preventing serious complications.\nNutritional optimization, including adequate intake of B vitamins, antioxidants, and essential nutrients, supports the neurotropic effects of Methylcobalamin. Avoiding alcohol and tobacco, both of which can exacerbate neuropathy, is strongly recommended.\nPatients should be cautioned about activities requiring alertness, such as driving or operating machinery, especially during the initial treatment phase when dizziness and somnolence may be more pronounced. These effects typically improve with continued therapy, but individual responses vary.\nConclusion\nEPSTATE ED represents a thoughtfully designed pharmaceutical formulation that addresses the multifaceted nature of diabetic neuropathy and neuropathic pain through its unique combination of Pregabalin, Epalrestat, and Methylcobalamin. This triple-action approach offers patients more than symptomatic relief—it provides genuine disease modification potential, nutritional support, and comprehensive nerve health optimization.\nThe synergistic effects of these three components create a therapeutic profile that is greater than the sum of its parts. While Pregabalin efficiently manages pain symptoms and improves quality of life in the short term, Epalrestat works to address underlying metabolic derangements that drive disease progression, and Methylcobalamin provides essential neurotropic support for nerve regeneration and function.\nFor patients struggling with the debilitating effects of neuropathic pain and diabetic neuropathy, EPSTATE ED offers renewed hope for better symptom control and potentially slowed disease progression. The convenience of combination therapy in a single tablet improves adherence and simplifies complex treatment regimens.\nHowever, EPSTATE ED is not without considerations. Potential side effects, though generally manageable, require awareness and monitoring. The medication is most effective when integrated into a comprehensive management plan that includes optimal glycemic control, lifestyle modifications, and regular medical supervision.\nUltimately, EPSTATE ED should be viewed as a valuable tool in the therapeutic arsenal against neuropathic conditions, best utilized under the guidance of knowledgeable healthcare professionals who can individualize treatment to each patient's unique needs and circumstances. With proper use, monitoring, and patient education, EPSTATE ED can significantly improve outcomes and quality of life for those affected by these challenging neurological conditions.",
"price": 275.0,
"discountamount": 82.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2253,
"imageuri": "https://productimages.withfloats.com/actual/694cf859d25fa0b0657b1ac8.png",
"tileimageuri": "https://productimages.withfloats.com/tile/694cf859d25fa0b0657b1ac8.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-12-25T08:39:48.947Z",
"updatedon": "2026-04-18T09:21:49.885Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//pregabalin-epalrestat-and-methylcobalamin-tablets/2253",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "EPSTATE ED",
"category": "NEUROLOGYRANGE",
"tags": [
"regabalin, Epalrestat, and Methylcobalamin.neuropathic pain conditions.",
"Pregabalin, Epalrestat, and Methylcobalamin.",
"neuropathic pain.",
"diabetic neuropathy.",
"sorbitol within nerve cells leads to osmotic stress.",
"Epalrestat and neurotropic support via Methylcobalamin creates an environment .",
"mood alterations, anxiety, depression, agitation.",
"supports the neurotropic effects of Methylcobalamin.",
"Pregabalin Epalrestat and Methylcobalamin Tablets",
"epalrestat and methylcobalamin tablets uses",
"epalrestat and methylcobalamin tablets in hindi",
"pregabalin epalrestat and methylcobalamin tablets price jaipur",
"pregabalin epalrestat and methylcobalamin tablets price india"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "694919f0de5d3e57a93413a8",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "elagolix 150mg tablet",
"description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n\tDaily activity restoration\nBleeding Control\t70% volume drop \n\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n\tSustained relief\nQoL Improvement\tEQ-5D gains \n\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n\tVentilation, timing\nHeadache\t17% \n\tAnalgesics\nBMD Loss\t0.9% \n\tSupplements, scans\nMood Shifts\t5% \n\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n",
"price": 700.0,
"discountamount": 210.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2252,
"imageuri": "https://productimages.withfloats.com/actual/694a2af01e4092f757d90bb5.png",
"tileimageuri": "https://productimages.withfloats.com/tile/694a2af01e4092f757d90bb5.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-12-22T10:14:08.773Z",
"updatedon": "2026-03-26T05:59:45.544Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//elagolix-150mg-tablet/2252",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "ELIGOLUX 150",
"category": "GYANECOLOGYRANGE",
"tags": [
"elagolix 150mg tablet",
"prioritizing bone health.",
"endometriotic pain.",
"endometrial tissue proliferation outside the uterus.",
"Eligolux 150 empowers women with moderate endometriosis pain through precise.",
"hormonal modulation and proven outcomes.",
"gonadotropins.",
"endometriotic pain."
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "66d6df52731125bdd4e1003b",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "VALGANCICLOVIR TABLET 450 MG",
"description": "VOLANE SOURCE 450 is a pharmaceutical tablet containing Valganciclovir at a dosage strength of 450 mg. It is a potent antiviral medication primarily designed to treat and prevent certain viral infections caused by cytomegalovirus (CMV), especially in immunocompromised patients such as those undergoing organ transplants or living with HIV/AIDS. Manufactured adhering to strict quality standards under the tablet IP (Indian Pharmacopoeia), VOLANE SOURCE 450 ensures consistent efficacy and safety for patients requiring antiviral therapy.\n\nComposition and Pharmacological Profile\nEach film-coated tablet of VOLANE SOURCE 450 contains 450 mg of Valganciclovir as the active ingredient. Valganciclovir is a prodrug of ganciclovir, meaning it is converted in the body into ganciclovir, which is the active antiviral agent. Its mechanism involves inhibiting viral DNA synthesis by competing with deoxyguanosine triphosphate for incorporation into viral DNA, thereby suppressing the replication of CMV and related herpes viruses.\n\nPrimary Uses of VOLANE SOURCE 450\nTreatment of CMV Retinitis: CMV retinitis is a serious viral eye infection common in patients with weakened immune systems, such as AIDS patients. It leads to inflammation and possible vision loss if left untreated. VOLANE SOURCE 450 is a frontline therapy used to halt the progression of this infection.\n\nPrevention of CMV Disease in Transplant Patients: Solid organ transplant recipients and bone marrow transplant patients are at high risk of CMV infection due to immunosuppressive drugs. Prophylactic use of VOLANE SOURCE 450 helps in preventing CMV disease in these vulnerable groups.\n\nTreatment of CMV Infection: Apart from retinitis, CMV can cause systemic infections affecting multiple organs, including lungs, digestive tract, and nervous system. VOLANE SOURCE 450 is used for managing such infections effectively.\n\nPart of Combination Therapy: It may also be prescribed alongside other antiviral agents as part of combination treatment protocols tailored to complex viral infections, enhancing viral suppression.\n\nKey Benefits of Using VOLANE SOURCE 450\nHigh Oral Bioavailability: Being a prodrug, Valganciclovir is well absorbed orally and converted efficiently to ganciclovir in the body, enabling effective antiviral levels.\n\nWide Spectrum of Action: Targets multiple herpesviruses with high specificity, primarily cytomegalovirus, reducing viral load and infection severity.\n\nReduced Risk of CMV Disease Post-Transplant: By preventing CMV infection in transplant recipients, VOLANE SOURCE 450 significantly lowers the risk of post-transplant complications related to viral disease.\n\nConvenient Oral Dosage: Unlike intravenous ganciclovir, VOLANE SOURCE 450 allows for easier home administration, improving patient compliance and quality of life.\n\nEffective Against Resistant Strains: Used in recurrent and resistant CMV infections, especially where other therapies fail.\n\nProtects Vision: In CMV retinitis patients, prompt use of VOLANE SOURCE 450 can preserve vision and prevent blindness due to viral damage.\n\nRecommended Dosage and Administration\nThe dosing of VOLANE SOURCE 450 depends on the condition being treated, kidney function, and patient immune status. It is typically prescribed by healthcare professionals following careful medical assessment.\n\nFor CMV retinitis treatment, the initial dose is usually higher and then tapered down for maintenance.\n\nFor CMV prophylaxis post-transplant, a standard dose is taken once or twice daily for several months.\n\nIt is advised to swallow tablets whole with food to enhance absorption.\n\nRegular monitoring of blood counts and kidney function is essential during therapy since the drug can impact bone marrow and renal function.\n\nPotential Side Effects of VOLANE SOURCE 450\nLike any potent antiviral medication, VOLANE SOURCE 450 can cause side effects. Awareness and timely reporting to a healthcare provider are important to manage these effects safely.\n\nCommon side effects include:\n\nGastrointestinal symptoms: Nausea, vomiting, diarrhea, and abdominal pain.\n\nBone marrow suppression: Leading to anemia, neutropenia (low neutrophils), or thrombocytopenia (low platelets), which increase infection risks and bruising.\n\nHeadache and fatigue: Mild to moderate headache and tiredness may occur.\n\nFever and infections: Due to immune suppression, secondary infections may arise.\n\nElectrolyte imbalance: Occasionally, abnormalities in blood calcium or potassium levels.\n\nRare hypersensitivity reactions: Skin rash, itching, or swelling which require immediate medical attention.\n\nPrecautions and Contraindications\nPatients with severe renal impairment require dose adjustments or alternative therapies to avoid toxicity.\n\nPregnant or breastfeeding women should avoid this drug due to potential harm to the fetus or infant.\n\nRegular blood tests are necessary to monitor for hematologic or renal side effects.\n\nUse caution in patients with pre-existing neutropenia or anemia.\n\nConclusion\nVOLANE SOURCE 450 (Valganciclovir Tablet IP 450 mg) represents a reliable and efficacious antiviral therapy specifically targeting cytomegalovirus infections. Its role in treatment and prevention of CMV-related diseases, especially among immunocompromised patients, makes it invaluable in clinical practice.\n\nIts oral formulation allows for easy administration and effective drug delivery, improving patient adherence and outcomes. While the risk of side effects exists, careful monitoring and adherence to prescribed dosages minimize complications.\n\nOverall, VOLANE SOURCE 450 offers a potent solution against serious viral infections, helping preserve health, prevent complications, and improve quality of life for vulnerable patient populations.\n\n",
"price": 3944.0,
"discountamount": 2367.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"viral DNA",
"rare cases",
"Key Benefits",
"CMV Retinitis",
"VOLANE SOURCE",
"CMV infection",
"various organs",
"kidney function",
"prescribed course",
"chain termination",
"active ingredient",
"organ transplants",
"medical condition",
"blood cell counts",
"healthcare provider",
"severe side effects",
"Common Side Effects",
"Regular blood tests",
"complete eradication",
"antiviral medication",
"high bioavailability",
"severe eye infection",
"Serious Side Effects",
"high-risk individuals",
"convenient oral option",
"bone marrow suppression",
"weakened immune systems",
"VALGANCICLOVIR TABLET IP",
"High Oral Bioavailability",
"Immediate medical attention"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1950,
"imageuri": "https://productimages.withfloats.com/actual/6936b55236477d52c1e94700.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6936b55236477d52c1e94700.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-09-03T10:05:06.943Z",
"updatedon": "2026-03-12T06:40:40.942Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//valganciclovir-tablet-450-mg/1950",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "VOLANE SOURCE 450",
"category": "CARDIOLOGYRANGE",
"tags": [
"VALGANCICLOVIR TABLET IP 450 MG USUE",
"Valganciclovir Tablet IP 450 mg",
"infections caused by cytomegalovirus (CMV).",
"VOLANE SOURCE 450",
"helps control the spread of the CMV infection within the body",
"high bioavailability",
"improve quality of life for vulnerable patient populations",
"valganciclovir tablet 450 mg uses",
"valganciclovir 450 mg tablet price in India",
"valganciclovir 450 mg dosage information",
"valganciclovir tablet 450 mg composition",
"valganciclovir 450 mg tablet side effects",
"valganciclovir 450 mg tablet benefits",
"what is valganciclovir tablet 450 mg used for",
"how valganciclovir 450 mg works",
"valganciclovir 450 mg tablet mechanism of action",
"valganciclovir tablet 450 mg storage instructions",
"valganciclovir 450 mg tablet administration guide",
"buy valganciclovir 450 mg tablet online",
"valganciclovir 450 mg tablet supplier India",
"valganciclovir tablet 450 mg wholesale price",
"valganciclovir 450 mg tablet manufacturer",
"valganciclovir 450 mg tablet distributor",
"valganciclovir 450 mg generic tablet",
"valganciclovir 450 mg tablet substitute",
"valganciclovir 450 mg antiviral tablet",
"when to take valganciclovir 450 mg tablet"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "6661a73687f0960e14a2c739",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "mycophenolate sodium 360 mg",
"description": "MYCOPLASM S 360 \nMycophenolate sodium 360 mg is an essential immunosuppressant medication designed to prevent organ transplant rejection, particularly for kidney, heart, and liver transplants. As the sodium salt of mycophenolic acid, it delivers 360 mg of the active moiety per tablet, providing targeted immune suppression to help patients maintain their new organs long-term. This product stands out for its enteric-coated formulation, which enhances gastrointestinal tolerability compared to other forms, making it a preferred choice in post-transplant care regimens.\n\nUses of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg primarily serves as a prophylactic agent against acute rejection in adult and pediatric patients receiving allogeneic renal, cardiac, or hepatic transplants. It works alongside other immunosuppressants like cyclosporine and corticosteroids to create a balanced regimen that minimizes the risk of graft loss. Clinically, it proves effective in de novo transplant recipients, where starting therapy early post-surgery significantly reduces rejection episodes. Beyond transplants, off-label applications include managing refractory autoimmune conditions such as lupus nephritis or myasthenia gravis, where immune overactivity damages tissues.\n\nThe drug targets the proliferation of T- and B-lymphocytes, key players in immune responses that can attack transplanted organs. In renal transplant patients, for instance, it helps preserve kidney function by curbing antibody-mediated rejection. Its role extends to maintenance therapy, where consistent dosing sustains immunosuppression without excessive toxicity. Healthcare providers often adjust it based on patient response and trough levels of the active metabolite, mycophenolic acid (MPA), ensuring optimal therapeutic outcomes.\n\nKey Benefits of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg offers several advantages that make it a cornerstone in transplant medicine. One primary benefit is its selective inhibition of lymphocyte proliferation, sparing other cell types and reducing broad-spectrum immunosuppression risks. This leads to fewer opportunistic infections compared to older agents like azathioprine. The enteric coating minimizes upper GI upset, improving patient compliance—studies show higher adherence rates with this formulation.\n\nEnhanced Graft Survival: Prolongs organ viability by effectively suppressing cell-mediated and humoral immunity, with clinical data showing reduced biopsy-proven rejection rates.\n\nImproved Tolerability: Lower incidence of nausea and diarrhea due to delayed-release technology, allowing twice-daily dosing without food restrictions.\n\nFlexible Dosing: Equivalent to 720 mg mycophenolate mofetil, but with predictable MPA exposure via enterohepatic recirculation for steady-state efficacy.\n\nPediatric Suitability: Approved for children over 2 years in renal transplants, supporting growth without compromising safety.\n\nCost-Effective Long-Term Option: Balances efficacy and side effect profile, potentially lowering overall healthcare costs from fewer rejections or hospitalizations.\n\nPatients experience better quality of life, with sustained energy levels and fewer interruptions from acute rejection crises. Its metabolism to MPA via liver glucuronidation ensures reliable pharmacokinetics, even in patients with mild renal impairment.\n\nSide Effects of Mycophenolate Sodium 360 mg\nWhile highly effective, mycophenolate sodium 360 mg carries risks typical of immunosuppressants, necessitating vigilant monitoring. Common adverse effects stem from its impact on rapidly dividing cells, particularly in the gut and bone marrow.\n\nCommon Side Effects\nGastrointestinal issues like diarrhea, nausea, vomiting, and abdominal pain, affecting up to 30-50% of users.\n\nHeadache, insomnia, and tremor, often mild and transient.\n\nInfections such as urinary tract or respiratory, due to moderated immunity.\n\nHypertension or peripheral edema, manageable with supportive care.\n\nLeukopenia or anemia, requiring periodic blood counts.\n\nSerious Side Effects\nSevere myelosuppression leading to neutropenia or thrombocytopenia, which can increase infection or bleeding risks.\n\nProgressive multifocal leukoencephalopathy (PML), a rare brain infection linked to JC virus reactivation.\n\nGastrointestinal perforation or bleeding, especially in at-risk patients.\n\nIncreased malignancy risk, including lymphoma or skin cancers, over long-term use.\n\nHypersensitivity reactions like rash or anaphylaxis.\n\nRegular complete blood counts, viral monitoring (e.g., CMV, BK virus), and skin exams mitigate these risks. Dose reductions or discontinuation may be needed if counts drop significantly.\n\nMechanism of Action\nMycophenolate sodium 360 mg rapidly hydrolyzes to mycophenolic acid (MPA), a potent, reversible, non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH). This enzyme catalyzes the rate-limiting step in de novo guanine nucleotide synthesis, depleting guanosine nucleotides essential for T- and B-cell DNA replication. Lymphocytes, reliant on this pathway, undergo proliferation arrest, suppressing both cell-mediated immunity and antibody production.\n\nMPA also hinders glycosylation of adhesion molecules on lymphocytes and monocytes, impeding their migration to graft sites. It reduces nitric oxide production in macrophages without affecting endothelial cells, curbing inflammation. Enterohepatic recirculation of the glucuronide metabolite (MPAG) prolongs MPA exposure, enhancing efficacy. Protein binding to albumin (around 97%) ensures targeted delivery, with clearance primarily renal for the inactive form.\n\nDosage and Administration Guidelines\nStandard dosing for renal transplant is 720 mg (two 360 mg tablets) twice daily, starting within 72 hours post-surgery. Adjustments occur for hepatic or cardiac transplants, often alongside cyclosporine. Therapeutic drug monitoring of MPA AUC (area under curve) optimizes levels between 30-60 mcg·h/mL. Take on an empty stomach for best absorption, though food has minimal impact due to the coating.\n\nPrecautions and Warnings\nAvoid in pregnancy (Category D) due to teratogenicity—use contraception and regular pregnancy tests. Contraindicated in active untreated infections. Monitor for GI bleeding in ulcerative colitis patients. Drug interactions with antacids, cholestyramine, or rifampin alter MPA levels. Live vaccines are prohibited.\n\nConclusion\nMycophenolate sodium 360 mg represents a vital advancement in transplant immunosuppression, offering robust protection against rejection with a favorable benefit-risk profile. Its targeted action on lymphocytes, combined with improved GI tolerance, empowers patients to thrive post-transplant. By integrating it into comprehensive regimens with close monitoring, healthcare teams maximize graft success and patient well-being. Always consult a specialist for personalized guidance to harness its full potential safely.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \nhttps://www.sterisonline.com/product/mycoplasm-s-360-133670\n\n\n\n\n\n\n",
"price": 767.0,
"discountamount": 567.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"dose",
"risk",
"body",
"part",
"ORDER",
"360mg",
"Email",
"cells",
"dosage",
"nausea",
"vomiting",
"schedule",
"headache",
"strength",
"WhatsApp",
"diarrhea",
"activity",
"rejection",
"treatment",
"infections",
"supplements",
"information",
"MYCOPLASM S",
"sterispharma",
"sterisonline",
"stomach pain",
"blood counts",
"immune system",
"complications",
"liver problems",
"liver function",
"other medications",
"Regular monitoring",
"medical conditions",
"healthcare provider",
"Common side effects",
"Serious side effects",
"white blood cell count",
"potential drug interactions",
"optimal therapeutic effects",
"combination therapy regimen",
"organ transplant recipients",
"Mycophenolate Sodium therapy",
"other immunosuppressive drugs"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1474,
"imageuri": "https://productimages.withfloats.com/actual/6661a739c749b7962dbc08c6.jpg",
"tileimageuri": "https://productimages.withfloats.com/tile/6661a739c749b7962dbc08c6.jpg",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T12:10:30.488Z",
"updatedon": "2026-03-12T08:02:36.733Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//mycophenolate-sodium-360-mg/1474",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "MYCOPLASM S 360 ",
"category": "Oncology",
"tags": [
"MYCOPLASM S 360",
"Mycophenolate sodium (360mg)",
"Mycophenolate sodium 360 mg price",
"Mycophenolate sodium 360 mg brands",
"Mycophenolate sodium 360 mg side effects",
"Myfortic 360 alternative",
"Myfortic 500"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "666163aa8e599e12c0eaa3bc",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Cephalexin 375mg",
"description": "CEPHAHELIX 375 \nCephalexin 375mg\nIntroduction to Cephalexin 375mg\n\nCEPHAHELIX 375 is a highly effective antibiotic formulation containing Cephalexin 375 mg. It belongs to the cephalosporin class of antibiotics, widely prescribed for treating a variety of bacterial infections. This medicine works by eliminating harmful bacteria from the body, helping patients recover quickly and safely.\n\nHealthcare professionals trust CEPHAHELIX 375 for its proven efficacy, safety profile, and broad-spectrum antibacterial activity. It is commonly used in clinical settings for both mild and moderate infections.\n\nHow CEPHAHELIX 375 Works\n\nCephalexin works by targeting the bacterial cell wall. It interferes with the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Without a properly formed cell wall, bacteria cannot survive, leading to their destruction.\n\nThis mechanism makes CEPHAHELIX 375 bactericidal (kills bacteria) rather than bacteriostatic (just inhibits growth), ensuring faster infection control.\n\nUses of CEPHAHELIX 375\n\nCEPHAHELIX 375 is widely prescribed for treating several bacterial infections, including:\n\n1. Respiratory Tract Infections\nBronchitis\nPneumonia\nThroat infections (like tonsillitis and pharyngitis)\n2. Skin and Soft Tissue Infections\nCellulitis\nBoils and abscesses\nWound infections\n3. Urinary Tract Infections (UTIs)\nCystitis\nPyelonephritis (mild cases)\n4. Ear and Sinus Infections\nOtitis media\nSinusitis\n5. Bone Infections\nOsteomyelitis (as part of combination therapy)\n\nCEPHAHELIX 375 is effective against both Gram-positive and some Gram-negative bacteria, making it a versatile antibiotic option.\n\nKey Benefits of CEPHAHELIX 375\n1. Broad-Spectrum Antibiotic\n\nCephalexin effectively targets a wide range of bacteria, making it suitable for multiple types of infections.\n\n2. Fast Action\n\nPatients often start experiencing symptom relief within a few days of starting the medication.\n\n3. Well-Tolerated\n\nCompared to many antibiotics, Cephalexin has a relatively low incidence of severe side effects.\n\n4. High Patient Compliance\n\nAvailable in convenient oral dosage forms, CEPHAHELIX 375 is easy to administer.\n\n5. Effective for Recurrent Infections\n\nIt is often prescribed in cases of recurring infections due to its reliable efficacy.\n\n6. Suitable for Various Age Groups\n\nWith proper dosage adjustments, it can be used in both adults and children (as prescribed by a doctor).\n\nDosage and Administration\nThe dosage of CEPHAHELIX 375 depends on the severity and type of infection.\nTypically taken 2–4 times a day as directed by a physician.\nIt can be taken with or without food, although taking it with food may reduce stomach upset.\nComplete the full course even if symptoms improve early to prevent antibiotic resistance.\nPossible Side Effects of CEPHAHELIX 375\n\nLike all medications, CEPHAHELIX 375 may cause some side effects. Most are mild and temporary.\n\nCommon Side Effects\nNausea\nVomiting\nDiarrhea\nAbdominal pain\nIndigestion\nLess Common Side Effects\nSkin rash\nDizziness\nFatigue\nRare but Serious Side Effects\nSevere allergic reactions (anaphylaxis)\nClostridium difficile-associated diarrhea\nLiver function changes\n\nIf any severe or persistent side effects occur, medical attention should be sought immediately.\n\nPrecautions and Warnings\nAllergy Alert: Avoid if allergic to cephalosporins or penicillin-type antibiotics.\nKidney Disorders: Dose adjustment may be required in patients with renal impairment.\nPregnancy & Breastfeeding: Use only under medical supervision.\nDrug Interactions: Inform your doctor about all medications you are taking.\nStorage Instructions\nStore in a cool, dry place away from direct sunlight.\nKeep out of reach of children.\nDo not use after the expiry date.\nWhy Choose CEPHAHELIX 375?\n\nCEPHAHELIX 375 stands out in the pharmaceutical market due to the following:\n\nReliable quality formulation\nConsistent therapeutic outcomes\nCost-effective antibiotic solution\nTrusted by healthcare professionals\n\nIt is an ideal choice for hospitals, clinics, and pharmacies looking for dependable antibiotic products.\n\nConclusion\n\nCEPHAHELIX 375 (Cephalexin 375mg) is a powerful and dependable antibiotic designed to treat a wide range of bacterial infections effectively. Its fast-acting mechanism, broad-spectrum activity, and favorable safety profile make it a preferred choice among healthcare providers.\n\n\n\n\n\n\n",
"price": 178.0,
"discountamount": 54.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"Call",
"bone",
"skin",
"Email",
"375mg",
"growth",
"nausea",
"dosage",
"doctor",
"variety",
"diarrhea",
"concerns",
"WhatsApp",
"vomiting",
"treatment",
"Cephalexin",
"medication",
"antibiotic",
"CEPHAHELIX",
"information",
"full course",
"sterispharma",
"sterisonline",
"Side effects",
"urinary tract",
"respiratory tract",
"allergic reactions",
"healthcare provider",
"bacterial infections"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1414,
"imageuri": "https://productimages.withfloats.com/actual/666163ae4328177af1cfeadb.png",
"tileimageuri": "https://productimages.withfloats.com/tile/666163ae4328177af1cfeadb.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T07:22:18.57Z",
"updatedon": "2026-04-06T06:42:15.26Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//cephalexin-375mg/1414",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "CEPHAHELIX 375 ",
"category": "GENERAL RANGE",
"tags": [
"cephalexin 375",
"cephalexin 375 mg",
"cephalexin 375 mg uses in hindi",
"cephalexin 375 mg tablet",
"cephalexin 375 mg uses",
"cephalexin 375 mg price in india",
"buy cephalexin 375 mg online india",
"cephalexin 375 mg bulk order manufacturer",
"cephalexin 375 mg best price supplier",
"cephalexin 375 mg how to use"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "6ad7442bf24c5a4bbccf4b10",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Empagliflozin,Sitagliptin And Metformin Hydrochloride (ER) Tablets",
"description": "GLIEMPAFLOZIN 3D 25 is a combination pharmaceutical product containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This triple-combination formulation is intended for the management of type 2 diabetes mellitus in appropriate patients, as determined by a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help control blood glucose levels. Empagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin is a biguanide antidiabetic medicine. Together, these ingredients target different pathways involved in glucose regulation.\n\nGLIEMPAFLOZIN 3D 25 provides a combination of three established antidiabetic agents in a single tablet. Its suitability depends on the patient's blood glucose levels, kidney function, current diabetes treatment, medical history, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 25\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 25 mg: An SGLT2 inhibitor that helps the kidneys remove glucose from the bloodstream through urine.\nSitagliptin 100 mg: A DPP-4 inhibitor that increases the activity of incretin hormones involved in glucose-dependent insulin release and glucagon regulation.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, administration instructions, and approved indications should be verified against the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 25\nGLIEMPAFLOZIN 3D 25 combines three antidiabetic ingredients with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: The ingredients act through different mechanisms involved in blood glucose regulation.\nExtended-release metformin: The ER formulation is designed to release metformin over an extended period.\nOral tablet dosage form: Provides oral administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered by a healthcare professional when combination therapy is appropriate.\nThe benefits of this combination depend on the patient's clinical needs and the suitability of all three ingredients.\n\nUses of GLIEMPAFLOZIN 3D 25 Tablets\nGLIEMPAFLOZIN 3D 25 is intended for the management of type 2 diabetes mellitus, subject to the product's approved indications and the prescribing healthcare professional's judgment.\n\nType 2 diabetes is a chronic metabolic condition in which the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood glucose levels. Long-term elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three medicines in GLIEMPAFLOZIN 3D 25 target different aspects of glucose regulation. A healthcare professional may consider a combination regimen when an individual's treatment goals are not adequately achieved with a simpler regimen or when the combination is otherwise clinically appropriate.\n\nThe medicine should be used alongside an individualized diabetes-management plan that may include a balanced diet, physical activity, glucose monitoring, and regular medical follow-up. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 25 Work?\nThe three active ingredients contribute to blood glucose management through distinct mechanisms.\n\n1. Empagliflozin 25 mg\nEmpagliflozin inhibits SGLT2, a protein responsible for reabsorbing much of the glucose filtered by the kidneys. By reducing glucose reabsorption, it increases glucose excretion through urine and helps lower blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. These benefits depend on the patient's condition and the applicable prescribing information and should not be assumed to apply identically to every patient.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. Increasing incretin activity helps stimulate insulin release when blood glucose is elevated and reduces glucagon secretion when appropriate. This helps regulate glucose levels, particularly after meals.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily decreases glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nBy combining these mechanisms, GLIEMPAFLOZIN 3D 25 targets several pathways involved in type 2 diabetes. Its overall effectiveness and safety depend on appropriate patient selection, dosing, and ongoing monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 25\nWhen prescribed for an appropriate patient, this combination may offer the following treatment advantages:\n\nMultiple mechanisms of action: Addresses glucose regulation through three different pharmacological pathways.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nOral combination therapy: Combines three medicines in one tablet, which may simplify a prescribed regimen compared with taking each ingredient separately.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nIndividualized treatment options: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThese potential advantages do not guarantee a particular result. Treatment effectiveness depends on adherence, diet, physical activity, individual health status, and medical supervision.\n\nDirections for Use\nGLIEMPAFLOZIN 3D 25 should be taken only as prescribed by a qualified healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or discontinue treatment without consulting your prescriber.\nAttend recommended appointments for blood glucose monitoring and kidney-function assessment.\nIf a dose is missed, follow the official patient information or ask your healthcare professional or pharmacist for advice. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 25 is a prescription medicine and is not suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important renal considerations, and the combination may be unsuitable at certain levels of kidney impairment.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients should discuss dehydration risk, low blood pressure, and fluid intake with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin can increase the risk of genital fungal infections and may be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, excessive alcohol intake, or other predisposing conditions.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nLow blood glucose: The risk of hypoglycemia may increase when this combination is used with insulin or insulin secretagogues, such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, or an upcoming medical procedure involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, unusual weakness, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 25?\nGLIEMPAFLOZIN 3D 25 brings together Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER in a triple-combination tablet designed for the management of type 2 diabetes in appropriately selected patients.\n\nFor pharmaceutical product catalogues, distributors, pharmacies, and healthcare professionals, accurate information about the composition, mechanism of action, approved indications, and safety profile supports responsible product awareness.\n\nTreatment decisions should always be based on the patient's medical assessment and the approved product information.\n\nConclusion\nGLIEMPAFLOZIN 3D 25 Tablets combine Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. This combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 25?\n\nGLIEMPAFLOZIN 3D 25 is a combination tablet containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 25 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom the combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 25 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 25 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan as recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 25 suitable for everyone with diabetes?\n\nNo. Its suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and the approved prescribing information.",
"price": 230.0,
"discountamount": 69.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2504,
"imageuri": "https://productimages.withfloats.com/actual/6ad7442d6e565c5fe6e5b7cb.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6ad7442d6e565c5fe6e5b7cb.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-10-20T10:36:27.325Z",
"updatedon": "2026-10-20T10:36:27.325Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//empagliflozin-sitagliptin-and-metformin-hydrochloride-er-tablets/2504",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIEMPAFLOZIN 3D 25",
"category": "DIABETIC RANGE",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6a86e496cc4491de1ed77dfd",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Etoricoxib & Cyclobenzaprine Hydrochloride Tablets",
"description": "ERITOCOX BENZ 90/5 is a fixed-dose combination tablet pairing Etoricoxib 90 mg, a selective COX-2 anti-inflammatory, with Cyclobenzaprine Hydrochloride 5 mg, a centrally acting muscle relaxant. It is prescribed for short-term relief of acute musculoskeletal problems where pain, swelling, and muscle tightness occur together — think a sudden low-back strain, a stiff neck, or a flare-up of arthritis where the surrounding muscles clamp down defensively. Rather than treating the inflammation alone or the spasm alone, this tablet addresses both mechanisms in one dose, which can mean fewer pills and a more complete response for short, acute episodes. It is a prescription-only (Schedule H) medicine, produced under WHO-GMP and ISO-certified manufacturing standards by Steris Healthcare Pvt. Ltd. Typical side effects include drowsiness, dry mouth, and mild stomach upset; because the combination carries cardiovascular, gastrointestinal, and kidney considerations, it should only be used under a doctor's supervision. This page walks through what the tablet does, how it works, correct usage, safety information, and answers to the questions people most often ask.\n\nWhat Is ERITOCOX BENZ 90/5?\n\nPain from an acute back injury, a wrenched neck, or an arthritis episode almost never travels alone — it tends to bring a tense, guarded muscle along with it that makes every movement feel worse. ERITOCOX BENZ 90/5 was formulated with that pattern in mind, folding two separate mechanisms into a single tablet rather than requiring two prescriptions.\n\nActive Ingredient\tStrength\tRole\nEtoricoxib\t90 mg\tSelective COX-2 inhibitor for inflammatory pain\nCyclobenzaprine Hydrochloride\t5 mg\tCentrally acting skeletal muscle relaxant\n\nEach tablet is manufactured by Steris Healthcare Pvt. Ltd., a WHO-GMP and ISO-certified pharmaceutical company, so every batch meets verified potency and quality benchmarks.\n\nWhy This Combination Makes Sense\n\nMusculoskeletal pain is rarely a single-track problem. When tissue is injured or irritated, inflammation flares up locally — and nearby muscles frequently respond by tightening protectively. That protective tightening, the spasm, often becomes a pain generator of its own. Treat only the inflammation and the spasm can linger; treat only the spasm and the underlying inflammation keeps driving discomfort.\n\nERITOCOX BENZ 90/5 is built to intervene on both fronts at once:\n\nEtoricoxib addresses the chemical cascade responsible for pain and swelling at the injured site.\nCyclobenzaprine works through the central nervous system to calm the muscle guarding that so often rides alongside that pain.\nMechanism of Action: How ERITOCOX BENZ 90/5 Works\n\nEtoricoxib selectively inhibits the COX-2 enzyme — the enzyme the body ramps up at sites of tissue damage or irritation to manufacture prostaglandins, the chemical messengers behind pain, swelling, and localized heat. Because it targets COX-2 specifically rather than blocking both COX-1 and COX-2 the way older, non-selective NSAIDs do, etoricoxib is designed to control inflammatory pain while leaving more of the COX-1 activity that protects the stomach lining relatively undisturbed.\n\nCyclobenzaprine Hydrochloride takes a different route entirely — its primary site of action is the brainstem, not the muscle fiber itself. By dampening excessive motor signaling sent to skeletal muscle, it reduces spasm and stiffness without producing the broad muscle weakness that a directly-acting muscle agent might cause.\n\nPut together, the tablet delivers a two-pronged effect: peripheral anti-inflammatory action from etoricoxib, layered with central muscle relaxation from cyclobenzaprine.\n\n[Reviewer placeholder: insert verified pharmacokinetic data (onset, half-life, bioavailability) once confirmed by medical/regulatory team — do not publish unverified figures.]\n\nClinical Uses of ERITOCOX BENZ 90/5\n\nA physician may prescribe this combination for short-term management of acute conditions where pain, inflammation, and spasm show up together, including:\n\nCondition\tTypical Presentation\nAcute lower back pain\tPain with associated muscle guarding/spasm\nNeck strain / cervical spasm\tStiff, restricted neck movement\nSprains, strains, overuse injuries\tMusculoskeletal trauma with inflammatory pain\nOsteoarthritis flare-ups\tJoint pain accompanied by surrounding muscle tightness\nPostural or occupational muscle pain\tWork- or posture-related inflammation and tension\nMovement restriction linked to spasm\tReduced range of motion driven by muscular guarding\n\nSuitability for any of the above must be confirmed by a doctor based on your specific diagnosis and medical history.\n\nKey Benefits of ERITOCOX BENZ 90/5\nOne tablet, two mechanisms — anti-inflammatory pain relief and muscle-spasm relief combined, simplifying an otherwise two-drug regimen.\nSite-focused inflammation control — etoricoxib's COX-2 selectivity is intended to concentrate its effect where inflammation is actually active.\nA comparatively gentler GI footprint — COX-2-selective action is generally linked to lower gastrointestinal irritation risk than older non-selective NSAIDs, though vigilance is still warranted.\nLoosens spasm-related stiffness — cyclobenzaprine's central action helps release tight, guarded muscles restricting movement.\nAids functional recovery — easing both pain and spasm can make it more realistic to resume light activity, stretching, or physiotherapy once your doctor clears you.\nStreamlined short-course dosing — a once-daily schedule (as prescribed) cuts down pill burden versus taking an NSAID and a muscle relaxant separately.\nDosage & Administration\n\nThe following is general reference information — your doctor's specific prescription always takes precedence.\n\nTake ERITOCOX BENZ 90/5 exactly as prescribed, generally once a day, with or without food.\nSwallow the tablet whole with water; avoid crushing or chewing unless your doctor tells you otherwise.\nTreatment is typically short — anywhere from a few days to roughly two weeks — reflecting the acute, self-limiting nature of most pain-and-spasm episodes.\nIf a dose is missed, take it as soon as you remember, but skip it entirely if the next dose is nearly due. Never double up to make up for a missed dose.\nDo not extend the treatment period or adjust your dose independently, even if symptoms haven't fully resolved.\nSide Effects of ERITOCOX BENZ 90/5\nCommon Side Effects\nDrowsiness or sleepiness\nDizziness\nDry mouth\nHeadache\nStomach discomfort or indigestion\nNausea\nFatigue\nMild elevation in blood pressure in some individuals\nSerious Side Effects — Seek Medical Help Promptly\nSigns of gastrointestinal bleeding, such as black stools or vomiting blood\nA severe allergic reaction — swelling of the face or throat, breathing difficulty, or widespread rash\nChest pain, irregular heartbeat, or other symptoms suggestive of a cardiovascular event\nYellowing of the skin or eyes, which may point to liver involvement\nA noticeable drop in urine output, which may suggest kidney impairment\nSevere dizziness, confusion, or fainting\n\nIf any of these serious symptoms appear, stop the medicine and get medical attention immediately.\n\nPrecautions & Warnings\nShare your full medical history with your doctor before starting, including any heart, kidney, or liver conditions.\nUse cautiously — or avoid altogether — if you have a history of stomach ulcers or gastrointestinal bleeding.\nGenerally not advised for people with uncontrolled high blood pressure, existing heart disease, or a prior stroke, unless a doctor specifically clears its use.\nSteer clear of alcohol, since it can amplify cyclobenzaprine's sedative effect and add to gastrointestinal risk.\nCyclobenzaprine may cause drowsiness or dizziness — hold off on driving or operating machinery until you know how the tablet affects you.\nDon't combine ERITOCOX BENZ 90/5 with other NSAIDs, painkillers, or sedating medicines without checking with your doctor first.\nAvoid the medicine if you have known hypersensitivity to etoricoxib, cyclobenzaprine, or related compounds.\nNot generally recommended during pregnancy or breastfeeding unless a doctor specifically advises otherwise.\nAvoid combining with MAO inhibitors, or using shortly after stopping them.\nDrug Interactions to Flag With Your Doctor\n\nDisclose every prescription medicine, over-the-counter product, and supplement you take. Extra caution is needed around medicines affecting:\n\nBlood pressure regulation\nKidney function\nBlood clotting\nCentral nervous system activity (sedatives, other muscle relaxants)\nLiver metabolism\nOther anti-inflammatory or pain-relief medicines\nConclusion\n\nERITOCOX BENZ 90/5 brings Etoricoxib 90 mg and Cyclobenzaprine Hydrochloride 5 mg together to tackle a problem that rarely presents as a single issue — pain, inflammation, and muscle spasm that reinforce one another in acute musculoskeletal conditions. By acting on both the inflammatory and muscular sides of that cycle, it offers a more rounded short-term response than either ingredient could provide alone.\n\nGiven the genuine cardiovascular, gastrointestinal, kidney, and central-nervous-system considerations involved, ERITOCOX BENZ 90/5 is meant strictly for short, doctor-supervised courses — not casual or extended self-treatment. Always check with your doctor to confirm whether this combination is right for your condition, medical history, and current medications.\n\nPrescription only – consult your doctor.\n\nFrequently Asked Questions (Google & AI Mode / Voice Search Optimized)\n\n1. What is ERITOCOX BENZ 90/5 used for? It's typically prescribed for short-term relief of acute musculoskeletal issues — such as back pain, neck strain, or an arthritis flare-up — where pain, inflammation, and muscle spasm show up together.\n\n2. Is ERITOCOX BENZ 90/5 a muscle relaxant? It's a combination tablet: the muscle-relaxing effect comes from its Cyclobenzaprine Hydrochloride component, while Etoricoxib supplies the pain-relieving, anti-inflammatory action.\n\n3. Is Etoricoxib a strong painkiller? Etoricoxib is an effective selective COX-2 inhibitor typically used for moderate inflammation-related pain, such as arthritis or an acute musculoskeletal injury. Its appropriateness for your level of pain should be assessed by a doctor.\n\n4. Is Etoricoxib safe for the kidneys? As with other NSAIDs, etoricoxib can influence kidney function, particularly with extended use, higher doses, dehydration, or existing kidney disease. It should be used carefully and only under medical guidance if kidney health is a concern.\n\n5. Should ERITOCOX BENZ 90/5 be taken in the morning or at night? It's usually taken once a day at a time your doctor sets. Since cyclobenzaprine can cause drowsiness, many doctors lean toward an evening dose — but always stick to your specific prescription.\n\n6. What are the common side effects of ERITOCOX BENZ 90/5? Frequently reported effects include drowsiness, dizziness, dry mouth, headache, stomach discomfort, and mild fatigue. Most fade on their own, but persistent symptoms should be reported to your doctor.\n\n7. How fast does ERITOCOX BENZ 90/5 start working? Etoricoxib tends to absorb fairly quickly, and many people feel pain relief within roughly an hour, though onset can vary by individual and whether the tablet is taken with food.\n\n8. What should be avoided while on ERITOCOX BENZ 90/5? Skip alcohol, avoid taking other NSAIDs or painkillers without medical advice, and hold off on driving or operating machinery if you're feeling drowsy or dizzy.\n\n9. How many days can ERITOCOX BENZ 90/5 be taken? It's usually prescribed for a short stretch — a few days up to around two weeks — matching how acute conditions typically resolve. Anything longer needs your doctor's review.\n\n10. What are the benefits of ERITOCOX BENZ 90/5? It delivers combined relief from pain, inflammation, and muscle spasm in one tablet, which can make it easier to move normally and get back to daily activity sooner when used as directed.\n\n11. How safe is ERITOCOX BENZ 90/5? Taken exactly as prescribed and for the recommended duration, it's generally considered safe for most adults. It does carry cardiovascular, gastrointestinal, kidney, and liver-related risks that call for medical supervision, especially if you already have related conditions.\n\n12. Can ERITOCOX BENZ 90/5 be used for knee pain? Yes — its etoricoxib component is commonly used for joint pain tied to osteoarthritis or an acute injury, including the knee, by reducing the underlying inflammation. A doctor should confirm suitability first.\n\n13. Does ERITOCOX BENZ 90/5 cause drowsiness? Yes — drowsiness and dizziness are known effects linked to its cyclobenzaprine component. Avoid driving or tasks requiring full alertness until you know how it affects you.\n\n14. Can ERITOCOX BENZ 90/5 be bought without a prescription? No. This is a prescription-only medicine meant to be taken solely under a qualified doctor's supervision — it isn't meant for self-prescribing or extended use without medical oversight.\n\n15. Can ERITOCOX BENZ 90/5 be taken with food? It can generally be taken with or without food, though taking it with food may ease stomach discomfort for some people. Follow your doctor's specific instructions.\n\n16. Is ERITOCOX BENZ 90/5 habit-forming? Cyclobenzaprine isn't considered addictive with typical short-term use, but the tablet should still be taken only for the prescribed duration and not restarted on your own without medical advice.\n\n17. Who should avoid taking ERITOCOX BENZ 90/5? People with active stomach ulcers, significant heart, kidney, or liver disease, known hypersensitivity to NSAIDs, or those who are pregnant or breastfeeding should avoid it unless a doctor specifically clears its use.",
"price": 222.0,
"discountamount": 67.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2495,
"imageuri": "https://productimages.withfloats.com/actual/6a86e4990f089c4695c57658.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6a86e4990f089c4695c57658.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-08-20T11:27:18.403Z",
"updatedon": "2026-08-20T11:27:18.403Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//etoricoxib-cyclobenzaprine-hydrochloride-tablets/2495",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "ERITOCOX BENZ 90/5",
"category": "",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6a7722af7f45a0190eb37920",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Tolperisone Hydrochloride & Paracetamol Tablets",
"description": "TOPERITIME P 150/325: Dual-Action Relief for Musculoskeletal Pain and Spasms\nTOPERITIME P 150/325 is a prescription combination therapy formulated to treat acute musculoskeletal discomfort, muscle stiffness, and associated inflammatory pain. By uniting a centrally acting muscle relaxant with a proven analgesic, this film-coated tablet addresses both the neurological and physical aspects of muscle strain, restoring movement and facilitating recovery.\n\nActive Ingredients\nEach film-coated tablet contains:\n\nTolperisone Hydrochloride (150 mg): A muscle relaxant targeting involuntary contractions within the central nervous system.\n\nParacetamol (325 mg): A widely recognized analgesic and antipyretic agent that blocks pain signal transmission.\n\nAvailable in blister packaging and dispensed strictly under a licensed physician's order.\n\nTherapeutic Mechanism\nPainful muscle conditions often create a feedback loop where localized pain triggers involuntary spasms, which in turn exacerbate the pain. TOPERITIME P 150/325 disrupts this cycle through a two-pronged mechanism:\n\nNeuromuscular Regulation: Tolperisone Hydrochloride acts on the spinal cord and brainstem reflexes to inhibit hyperactive nerve impulses driving muscle tension. Unlike traditional skeletal muscle relaxants, it achieves this with minimal central nervous system depression, significantly reducing the likelihood of heavy sedation.\n\nNociceptive Blocking: Paracetamol inhibits prostaglandin synthesis within the central nervous system, raising the body's overall pain threshold and attenuating pain signals originating from injured tissues.\n\nBy simultaneously relaxing tight muscle fibers and dampening pain sensation, the formulation provides comprehensive symptomatic relief.\n\nClinical Indications\nHealthcare professionals may prescribe TOPERITIME P 150/325 for various acute and subacute conditions characterized by pain and hypertonia, including:\n\nAcute muscle spasms and athletic injuries\n\nAcute or chronic lower back pain (lumbago)\n\nCervical spine discomfort and stiff neck\n\nCervical and lumbar spondylosis\n\nFrozen shoulder (adhesive capsulitis)\n\nPost-operative or post-traumatic muscle recovery\n\nGeneralized connective tissue or orthopedic pain\n\nKey Clinical Features\nBalanced Dual Action: Simultaneously targets involuntary contractions and pain sensation.\n\nLow-Sedation Profile: Tolperisone allows patients to maintain daily function without severe daytime drowsiness typical of older relaxants.\n\nEnhanced Mobility: Reduces joint and tissue stiffness, enabling better engagement in physical rehabilitation.\n\nStreamlined Regimen: Combines two therapeutic agents into a single convenient dosage form.\n\nUsage Guidelines\nThis medication must be taken strictly in accordance with a medical prescription.\n\nAdministration: Swallow the tablet whole with water. Do not crush, chew, or split the film-coated tablet.\n\nTiming: Take immediately after a meal to reduce potential gastrointestinal upset, unless directed otherwise by a doctor.\n\nCompliance: Complete the full course prescribed by your physician, and do not alter the recommended dosage.\n\nPotential Side Effects\nWhile generally well-tolerated, some individuals may experience mild side effects, including:\n\nGastrointestinal distress or mild nausea\n\nTransient dizziness or lightheadedness\n\nHeadaches\n\nGeneral fatigue or muscular weakness\n\nRare: Hypersensitivity reactions or cutaneous skin rashes (discontinue use and consult a physician immediately if severe symptoms appear).\n\nSafety Precautions and Considerations\nConsult a medical practitioner prior to initiating treatment if any of the following apply:\n\nPre-existing hepatic (liver) or renal (kidney) impairment\n\nKnown hypersensitivity to Tolperisone, Paracetamol, or related compounds\n\nPregnancy, plans for pregnancy, or active breastfeeding\n\nHistory of chronic alcohol dependency (due to increased liver sensitivity with Paracetamol)\n\nConcurrent use of other medications, particularly other products containing Paracetamol or central nervous system depressants\n\nStorage and Handling\nStore in a cool, dry area below 25°C (77°F).\n\nProtect from direct light, heat, and moisture.\n\nKeep strictly out of reach of children and pets.\n\nCheck the packaging expiration date before administration.\n\nFrequently Asked Questions\nWhat primary conditions does TOPERITIME P 150/325 treat?\n\nIt is indicated for short-term relief from acute musculoskeletal pain, muscle spasms, neck strains, backaches, and related orthopedic disorders.\n\nWhy is Tolperisone combined with Paracetamol?\n\nTolperisone eases muscle tightness at the neurological level, while Paracetamol lowers overall pain perception, creating a synergistic effect that addresses both spasm and pain together.\n\nWill this medication cause severe drowsiness?\n\nTolperisone is specifically designed to exert less sedating activity compared to older muscle relaxants. However, individual sensitivity varies, so caution is advised when driving or operating machinery until individual tolerance is established.\n\nIs TOPERITIME P 150/325 available over the counter?\n\nNo. It requires a valid medical prescription and direct supervision by a registered healthcare professional.",
"price": 95.0,
"discountamount": 29.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2493,
"imageuri": "https://productimages.withfloats.com/actual/6a7722b0ed25653efa18364e.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6a7722b0ed25653efa18364e.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-08-08T12:35:59.075Z",
"updatedon": "2026-08-08T12:35:59.075Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//tolperisone-hydrochloride-paracetamol-tablets/2493",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "TOPERITIME P 150/325",
"category": "ORTHOLOGYRANGE",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
}
],
"hasmoreitems": false,
"isapirequest": false,
"totalresults": 27,
"query": null,
"floatingpoint": null
}